(Corrects CEO name in paragraph 1)
July 16 (Reuters) - Abbott Laboratories expects to see higher demand for serology and antibody testing for the new coronavirus, even after a vaccine becomes available, Chief Executive Officer Robert Ford said on a post-earnings conference call on Thursday.
The company, which has two antibody tests authorized for emergency use in the United States, said testing volumes in its underlying diagnostics unit, excluding COVID-19 tests, also rebounded to about 90% of pre-COVID levels by the end of the second quarter. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
Our Standards: The Thomson Reuters Trust Principles.